| 摘要 |
Compositions containing PBN, or active derivatives thereof, in a suitable pharma ceutical carrier for administration to a patient, are disclosed for treating or preventing gastric ulceration caused by i ngestion of non-steroidal anti-inflammatories. Based on animal studies, the dosage is in the range of 3 to 300 mg/kg and is administe red prior to, simultaneously, or shortly after ingestion of the NSAID compound(s). In the preferred embodiment, the rangee is b etween 10 and 30 mg/kg, depending on the dosage unit required to protect the mucosa. The preferred method of administrati on is orally, alone or in combination with the non-steroidal anti-inflammatory. It is believed that the PBN is also useful alon e for treatment or prevention of ulcers, aspects of diarrhea, gastritis, esophagitis, ileitis, and as an analgesic.
|
